This Journal feature begins with a case vignette highlighting a common clinical problem. Evidence supporting various strategies is then presented, followed by a review of formal guidelines, when they ...

Uterine fibroids are a common condition that affects up to 80% of women in their lifetime. Nearly half of those women will experience symptoms that affect their quality of life and fertility, ...

Embolization, a relatively new therapy for fibroid tumors that cuts off their blood supply, leads to quicker and less painful recoveries than hysterectomy. But the tumors often return. A team of ...

GENEVA, Switzerland May 9, 2022 – ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies for women’s health, today announced the presentation ...

The Phase 2 clinical trial of Merigolix in uterine fibroids was conducted by TiumBio's partner, Daewon Pharmaceutical, and enrolled a total of 71 women diagnosed with uterine fibroids. Participants ...

In a pre-clinical, proof-of-concept study from Johns Hopkins Medicine, researchers found that epigallocatechin gallate (EGCG), a green tea compound with powerful antioxidant properties, could be ...

In a pre-clinical, proof-of-concept study from Johns Hopkins Medicine, researchers found that epigallocatechin gallate (EGCG), a green tea compound with powerful antioxidant properties, could be ...

If an effective treatment is available for one common disease in men, and that same treatment is available for a different common disease in women, a logical expectation would be that the treatments ...

See more of our trusted coverage when you search. Prefer Newsweek on Google to see more of our trusted coverage when you search. It's easy to dismiss the women on the Real Housewives franchise as out ...

Fibroids are a common part of the female experience. These benign growths of uterine tissue will occur in 65 percent of women by age 50, and the prevalence is even higher in women of color. Despite ...